Cargando…
Differential prognostic factors in low‐ and high‐burden de novo metastatic hormone‐sensitive prostate cancer patients
Metastatic burden is a critical factor for therapy decision‐making in metastatic hormone‐sensitive prostate cancer. The present study aimed to identify prognostic factors in men with high‐ or low‐metastatic burden treated with primary androgen‐deprivation therapy. The study included 2450 men with de...
Autores principales: | Shiota, Masaki, Terada, Naoki, Saito, Toshihiro, Yokomizo, Akira, Kohei, Naoki, Goto, Takayuki, Kawamura, Sadafumi, Hashimoto, Yasuhiro, Takahashi, Atsushi, Kimura, Takahiro, Tabata, Ken‐ichi, Tomida, Ryotaro, Hashimoto, Kohei, Sakurai, Toshihiko, Shimazui, Toru, Sakamoto, Shinichi, Kamiyama, Manabu, Tanaka, Nobumichi, Mitsuzuka, Koji, Kato, Takuma, Narita, Shintaro, Yasumoto, Hiroaki, Teraoka, Shogo, Kato, Masashi, Osawa, Takahiro, Nagumo, Yoshiyuki, Matsumoto, Hiroaki, Enokida, Hideki, Sugiyama, Takayuki, Kuroiwa, Kentaro, Inoue, Takahiro, Mizowaki, Takashi, Kamoto, Toshiyuki, Kojima, Takahiro, Kitamura, Hiroshi, Sugimoto, Mikio, Nishiyama, Hiroyuki, Eto, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019198/ https://www.ncbi.nlm.nih.gov/pubmed/33159829 http://dx.doi.org/10.1111/cas.14722 |
Ejemplares similares
-
Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021) -
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer
por: Terada, Naoki, et al.
Publicado: (2020) -
Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022) -
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
por: Osawa, Takahiro, et al.
Publicado: (2020) -
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers
por: Mukai, Shoichiro, et al.
Publicado: (2020)